Imugene Reports Strong Response Rates in Azer-Cel Phase 1b Study.
Imugene Limited (ASX: IMU) has reported encouraging early results from the CAR T-naïve cohort of its Phase 1b basket trial evaluating azer-cel, an off-the-shelf allogeneic CAR T therapy targeting multiple advanced B-cell cancers.
The study recorded a 100% Overall Response Rate in patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, where all four treated patients achieved partial responses after receiving multiple prior lines of therapy. In Marginal Zone Lymphoma, the therapy delivered an 80% Overall Response Rate, including three complete responses and one partial response among five treated patients.
The basket trial structure allows Imugene to assess azer-cel across several B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Primary Central Nervous System Lymphoma, and Waldenström’s Macroglobulinemia, helping the company identify the most promising indications for potential registrational development.
Patient enrolment in the CAR T-naïve cohort is progressing strongly, reflecting growing clinical interest in an allogeneic CAR T approach. The company has also amended the protocol to evaluate Azer-Cel in combination with Bruton Tyrosine Kinase inhibitors and to include patients with mantle cell lymphoma, expanding the potential treatment scope.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imugene Reports Strong Response Rates in Azer-Cel Phase 1b Study.
Imugene Limited (ASX: IMU) has reported encouraging early results from the CAR T-naïve cohort of its Phase 1b basket trial evaluating azer-cel, an off-the-shelf allogeneic CAR T therapy targeting multiple advanced B-cell cancers.
The study recorded a 100% Overall Response Rate in patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, where all four treated patients achieved partial responses after receiving multiple prior lines of therapy. In Marginal Zone Lymphoma, the therapy delivered an 80% Overall Response Rate, including three complete responses and one partial response among five treated patients.
The basket trial structure allows Imugene to assess azer-cel across several B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Primary Central Nervous System Lymphoma, and Waldenström’s Macroglobulinemia, helping the company identify the most promising indications for potential registrational development.
Patient enrolment in the CAR T-naïve cohort is progressing strongly, reflecting growing clinical interest in an allogeneic CAR T approach. The company has also amended the protocol to evaluate Azer-Cel in combination with Bruton Tyrosine Kinase inhibitors and to include patients with mantle cell lymphoma, expanding the potential treatment scope.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au